Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
07:07pm, Thursday, 08'th Aug 2024
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago.
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
04:30pm, Monday, 29'th Jul 2024
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre
Tarsus to Participate in Upcoming Investor Conferences
05:00pm, Wednesday, 29'th May 2024
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
05:00pm, Thursday, 09'th May 2024
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript
09:45pm, Wednesday, 08'th May 2024
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants David Nakasone - Head of Investor Relations Bobby Azamian - Chief Executive Off
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Wednesday, 08'th May 2024
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to loss of $0.88 per share a year ago.
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
04:05pm, Wednesday, 08'th May 2024
Generated $24.7 million in net product sales of XDEMVY ® , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
10:56am, Monday, 06'th May 2024
The consensus price target hints at a 38.7% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
05:00pm, Wednesday, 01'st May 2024
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
10:56am, Monday, 08'th Apr 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 47.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questiona
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
01:00pm, Monday, 01'st Apr 2024
Tarsus Pharmaceuticals (TARS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
08:03pm, Thursday, 07'th Mar 2024
TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new indications with the US Food and Drug Administra
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
10:56am, Wednesday, 06'th Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Tarsus Pharmaceuticals, Inc. (TARS). While the effectiveness of this highly sought-after metric is que
Tarsus to Participate at Upcoming Investor Conferences
04:30pm, Tuesday, 05'th Mar 2024
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr
